Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593906 | SCV000704545 | uncertain significance | not provided | 2016-12-16 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001332567 | SCV001524937 | uncertain significance | Timothy syndrome | 2019-08-21 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Ambry Genetics | RCV004024757 | SCV003540001 | uncertain significance | Cardiovascular phenotype | 2021-09-01 | criteria provided, single submitter | clinical testing | The c.5435G>A (p.S1812N) alteration is located in exon 42 (coding exon 42) of the CACNA1C gene. This alteration results from a G to A substitution at nucleotide position 5435, causing the serine (S) at amino acid position 1812 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV000593906 | SCV004184207 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | CACNA1C: PM2 |